Adelaida La Casta - Concepedia

Author

Adelaida La Casta

Biogipuzkoa Health Research Institute ORCID

Also Known As

A Casta, A Lacasta, A. La Casta, A. LaCasta, A. Lacasta, Adelaida Casta, Adelaida La Casta, Adelaida La Casta Munoa, Adelaida La La Casta, Adelaida Lacasta

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Biogipuzkoa Health Research Institute Vall d'Hebron Hospital Universitari Instituto de Salud Carlos III Hospital Universitario Central de Asturias Hospital Universitario 12 De Octubre

About

Adelaida La Casta is an author at Biogipuzkoa Health Research Institute specializing in cancer research, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	388
2	Health Sciences	2	2	25
3	Cell Biology	1	1	101
4	Endocrinology	1	1	11
5	Gastroenterology	1	1	20

Adelaida La Casta

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry Laura Izquierdo‐Sánchez, Ángela Lamarca, Adelaida La Casta, Journal of Hepatology	2022	322
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma Ander Arbelaiz, Mikel Azkargorta, Marcin Krawczyk, Hepatology	2017	275
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study Eduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí, The Oncologist	2012	212
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis Jesús M. Bañales, Mercedes Iñarrairaegui, Ander Arbelaiz, Hepatology	2018	182
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma Ainhoa Lapitz, Mikel Azkargorta, Piotr Milkiewicz, Journal of Hepatology Tumor BiologyPrognostic BiomarkersEarly DiagnosisBiomarker (Medicine)Hepatology	2023	153
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms Aitor Esparza-Baquer, Ibone Labiano, Omar Sharif, Gut	2020	112
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509) Jaume Capdevila, Nicola Fazio, Carlos López, Journal of Clinical Oncology	2021	103
SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma Maite Merino-Azpitarte, Elisa Lozano, María J. Perugorria, Journal of Hepatology Tumor BiologyMedicineBiliary CancerPathologyCancer Biology	2017	101
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2 Teresa Macarulla, Roberto Pazo-Cid, Carmen Guillén‐Ponce, Journal of Clinical Oncology	2018	89
Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis Ainhoa Lapitz, Ander Arbelaiz, Colm J. O’Rourke, Cells	2020	89

Page 1